Program
bexmarilimab
Also written as “bexmarilimab (1mg/kg)”, “bexmarilimab (3mg/kg)” and “Bexmarilimab”.
Its studies are mostly in Neoplasms · Leukemia, Myeloid, Acute · Carcinoma, Renal Cell, led by Faron Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Faron Pharmaceuticals | 42 open or running | phase 2since Oct 23, 2018 | Oct 23, 2018 | Mar 2027phase 2 · NCT05428969 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 23, 2018First study: phase 2 study in NeoplasmsFirst studyNCT03733990 · 216 enrolled · United States, Finland, France and more
- Oct 22, 2021Phase 2 study in Carcinoma, Renal CellNCT05104905 · Finland
- Jun 15, 2022Phase 2 study in Leukemia, Myeloid, AcuteNCT05428969 · 181 enrolled · United States, Finland, United Kingdom
- Apr 27, 2026Phase 2 study in NeoplasmsNCT07672769 · 90 planned · United States, Czechia, Finland and more
Ahead
- Mar 2027Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT05428969
- Nov 2027Primary completion: phase 2 study in NeoplasmsNCT07672769
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07672769Neoplasms · United States, Czechia, Finland and more | 2 | Recruiting | Nov 2027 | 90 |
| NCT05428969Leukemia, Myeloid, Acute · United States, Finland, United Kingdom | 2 | Active, not recruiting | Mar 2027 | 181 |
| NCT05104905Carcinoma, Renal Cell · Finland | 2 | Withdrawn | Jan 28, 2022 | 0 |
| NCT03733990Neoplasms · United States, Finland, France and more | 2 | Completed | Sep 6, 2023 | 216 |
How it is read
Names in the registry
- “bexmarilimab (1mg/kg)”, 1 entry
- “bexmarilimab (3mg/kg)”, 1 entry
- “Bexmarilimab”, 1 entry
- “FP-1305 (bexmarilimab)”, 1 entry
- “bexmarilimab”, 1 entry
Conditions, from the studies’ own filings
- Neoplasms, 2 studies
- Leukemia, Myeloid, Acute, 1 study
- Carcinoma, Renal Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.